“The drug didn’t get any better. The cancer patients didn’t get any better. You just got better at making money.”
Watch Katie Porter use her signature precision to dismantle the former CEO of Celgene, Mark Alles. Porter reveals how the price of the cancer drug Revlimid skyrocketed from $215 to $763 per pill with zero improvements to the formula.
The most shocking part? The CEO’s personal $13 million bonus. This isn’t just a business strategy—it’s a moral failure.
source
